Isofol Medical AB (5IU) Price & Analysis

Compare

1 Followers

5IU Stock Chart & Stats

€0.05

€0.01(5.26%)

At close: Jan 08 4:00 PM EST

€0.05

€0.01(5.26%)

Day’s Range― - ―

52-Week Range€0.04 - €0.16

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€17.52M

Enterprise Value€152.68M

Total Cash (Recent Filing)€126.99M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.20

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding281,107,240

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.39

Price to Book (P/B)1.46

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Very Low Leverage (no Debt)A zero-debt capital structure materially lowers financial risk and interest burden, giving management flexibility to fund clinical programs and negotiate partner deals. Over 2–6 months this durable low leverage reduces solvency pressure and improves options for non-dilutive or partnership financing.

Improved Cash Burn TrendMarked reduction in operating cash outflows versus earlier years signals better cost discipline and program prioritization. That structural improvement lengthens runway per unit of capital raised, lowering near-term refinancing frequency and making it easier to reach clinical/regulatory inflection points with less dilution.

Focused Clinical-stage, Partner-focused Business ModelA lean, development-and-partnering model concentrates resources on advancing a single lead asset, limiting commercial build costs. This durable strategy suits small biotech—reducing fixed costs, enabling licensing or co-development, and improving scalability if clinical data supports partnering or out-licensing.

Bears Say

No Recent RevenueA cessation of revenue leaves the company fully pre-commercial and dependent on external capital to fund operations. Over a multi-month horizon this structural lack of product sales magnifies funding risk, limits reinvestment capacity, and makes operational continuity contingent on successful financing or partner deals.

Persistent And Sizable Net LossesOngoing annual net losses and ~-51.9M operating cash burn in 2025 indicate continued negative cash conversion. Structurally, sustained losses increase the frequency and size of required capital raises, dilute shareholders, and constrain ability to expand the pipeline or finance late-stage trials without outside funding.

Eroding Equity CushionMaterial decline in shareholders' equity over several years reflects accumulated losses and financing activity. This weaker capital buffer reduces capacity to absorb setbacks or extend operations without dilution, raising structural funding vulnerability and potentially weakening negotiation leverage with partners or lenders.

Isofol Medical AB News

Isofol to Showcase Cancer Drug Candidate at Key March Investor Events

Isofol Medical AB ( ($SE:ISOFOL) ) has shared an announcement. Isofol Medical AB, listed on Nasdaq Stockholm, develops...

4d ago

Isofol Reports Strong Early Data for Arfolitixorin in Difficult-to-Treat Colorectal Cancer

The latest update is out from Isofol Medical AB ( ($SE:ISOFOL) ). Isofol Medical has reported encouraging interim...

11d ago

Isofol strengthens arfolitixorin program with new EU patent and advancing trials

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB continued development of...

17d ago

Isofol Showcases Arfolitixorin Trial Design at ASCO GI as Phase Ib/II Study Advances

Isofol Medical AB ( ($SE:ISOFOL) ) has issued an announcement. Isofol Medical AB will participate in the ASCO...

2M ago

Isofol Medical to Showcase Arfolitixorin at Upcoming Investor Meetings

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB announced its participation...

3M ago

Isofol Medical Secures New Patent for Cancer Drug Candidate Arfolitixorin

Isofol Medical AB ( ($SE:ISOFOL) ) just unveiled an update. Isofol Medical AB announced that the European Patent...

4M ago

Isofol Medical AB Reports Key Developments in Interim Report

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB has released its...

4M ago

Isofol Medical AB Appoints Nomination Committee for 2026 AGM

Isofol Medical AB ( ($SE:ISOFOL) ) has issued an announcement. Isofol Medical AB has appointed a nomination committee...

4M ago

Isofol Medical AB to Host Investor Meeting on Arfolitixorin Progress

An announcement from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB announced an investor...

4M ago

Isofol Medical AB to Present at ESMO Cancer Congress

Isofol Medical AB ( ($SE:ISOFOL) ) just unveiled an announcement. Isofol Medical AB announced its participation in the...

5M ago

5IU FAQ

What was Isofol Medical AB’s price range in the past 12 months?

Isofol Medical AB lowest stock price was €0.04 and its highest was €0.16 in the past 12 months.

What is Isofol Medical AB’s market cap?

Isofol Medical AB’s market cap is €17.52M.

When is Isofol Medical AB’s upcoming earnings report date?

Isofol Medical AB’s upcoming earnings report date is May 19, 2026 which is in 73 days.

How were Isofol Medical AB’s earnings last quarter?

Isofol Medical AB released its earnings results on Feb 18, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.005.

Is Isofol Medical AB overvalued?

According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Isofol Medical AB pay dividends?

Isofol Medical AB does not currently pay dividends.

What is Isofol Medical AB’s EPS estimate?

Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Isofol Medical AB have?

Isofol Medical AB has 281,107,240 shares outstanding.

What happened to Isofol Medical AB’s price movement after its last earnings report?

Isofol Medical AB reported an EPS of -€0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.326%.

Which hedge fund is a major shareholder of Isofol Medical AB?

Currently, no hedge funds are holding shares in DE:5IU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Isofol Medical AB

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.